Skip to main content
. 2024 Jan 22;7(1):e2351700. doi: 10.1001/jamanetworkopen.2023.51700

Figure 5. Breast Cancer Variant Subtypes.

Figure 5.

A, The distribution of breast cancer subtypes among patients in the actionable cohort. B, Distribution of circulating tumor DNA (ctDNA) burden values by ESR1 variant assay concordance among patients with hormone receptor–positive breast cancer. The horizontal lines represent medians, while the boxes represent IQRs; whiskers represent 1.5 × IQRs. The dots represent outliers outside of these distributions. C, At the individual ESR1 variant level, variants detected in the breast cancer cohort are classified as either concordant or assay-unique (top), with concordance varying across genes. Assay-unique variants are separately categorized according to whether they were uniquely detected by ctDNA or solid-tissue testing (bottom). D, Sequential ctDNA monitoring of ESR1 variants in an individual patient with metastatic breast cancer. The variant allele frequencies (VAFs) of the 3 ESR1 variants plotted show distinct trajectories over time, with indicated therapies and outcomes shown below. AI indicates aromatase inhibitor.

aP < .001.